Sakoda Teppei, Kanamitsu Yoko, Mori Yasuo, Sasaki Kensuke, Yonemitsu Etsuko, Nagae Konosuke, Yoshimoto Goichi, Kamezaki Kenjiro, Kato Koji, Takenaka Katsuto, Miyamoto Toshihiro, Furue Masutaka, Iwasaki Hiromi, Akashi Koichi
Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan.
Center for Cellular and Molecular Medicine, Kyushu University Hospital, Japan.
Intern Med. 2017 Sep 15;56(18):2481-2485. doi: 10.2169/internalmedicine.8491-16. Epub 2017 Aug 21.
Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM. We herein report a RUXO-treated MF patient who developed recurrent subcutaneous Sweet's disease (SSD) that was successfully treated by the administration of systemic glucocorticoids. We performed allo-SCT as previously scheduled, resulting in a good clinical course without deterioration of SSD. RUXO administration, as well as MF itself, might therefore sometimes cause this rare non-infectious event.
异基因造血干细胞移植（allo-SCT）对骨髓纤维化（MF）患者具有治愈潜力；然而，其与高治疗相关死亡率（TRM）的关联仍是一个需要克服的重大障碍。芦可替尼（RUXO）是一种新型JAK1/2抑制剂，可作为一种桥接治疗，直到能够进行allo-SCT以降低TRM。我们在此报告一例接受RUXO治疗的MF患者，该患者发生了复发性皮下Sweet病（SSD），通过全身应用糖皮质激素成功治疗。我们按原计划进行了allo-SCT，临床过程良好，SSD未恶化。因此，使用RUXO以及MF本身有时可能会引发这种罕见的非感染性事件。
